# Psoriatic Arthritis Linked to Pembrolizumab in a Lung Cancer Patient: From Oncologist to Rheumatologist

## TL;DR

A lung cancer patient developed psoriatic arthritis after receiving pembrolizumab, highlighting the challenges of managing such immune-related side effects.

## Contribution

This case report highlights psoriatic arthritis as a rare immune-related adverse effect of pembrolizumab in lung cancer patients.

## Key findings

- A 69-year-old male developed psoriatic arthritis after pembrolizumab treatment for lung cancer.
- The case emphasizes the challenges in managing immune-related rheumatic adverse effects in oncology patients.

## Abstract

Immune-related rheumatic adverse effects (rheumatic IAEs) are commonly observed in patients undergoing immunotherapy for solid tumors and hematologic malignancies. The Romanian National Health Insurance House offers all patients free access to oncology medications and has significantly improved in recent years.

Here, we present a case of a 69-year-old male patient diagnosed with a bronchopulmonary neoplasm who developed psoriatic arthritis (PsA) after receiving immunotherapy with pembrolizumab, emphasizing the challenges of therapeutic management in this case.